Development of the controlled release- medicine for pain treatment using drug delivery system.

与给药前相比，控释利多卡因片明显提高了鼻黏膜平均疼痛阈值超过72小时。通过一些压力刺激感到疼痛表明该成分的利多卡因不能到达皮下组织，而只能到达粘膜的外层。副作用方面，几乎均为反应性浆液性鼻漏，未见肝损伤、肾损伤、全血细胞减少等明显严重不良事件。今后，单次给药控释利多卡因片有可能实现简单有效、副作用少的术后镇痛。

The controlled release- lidocaine sheet significantly raised mean pain thresholds in a nasal mucous membrane compared with that of preadministration more than 72 hours. Feeling a pain by some pressure stimulation suggested that lidocaine of the component could not reach subcutaneous tissue, but only an outer layer of a mucous membrane. As for side effects, almost all had reactive serous rhinorrhea, but obvious serious adverse events such as a liver injury, a renal injury, pancytopenia and the other were not observed. It may be possible to lead a single administration of the controlled release- lidocaine sheet to the simple and effective postoperative analgesia with few side effects in future.